[go: up one dir, main page]

DK3353168T3 - Forbindelser og fremgangsmåder til at inhibere jak - Google Patents

Forbindelser og fremgangsmåder til at inhibere jak Download PDF

Info

Publication number
DK3353168T3
DK3353168T3 DK16770031.9T DK16770031T DK3353168T3 DK 3353168 T3 DK3353168 T3 DK 3353168T3 DK 16770031 T DK16770031 T DK 16770031T DK 3353168 T3 DK3353168 T3 DK 3353168T3
Authority
DK
Denmark
Prior art keywords
compounds
methods
inhibiting jak
jak
inhibiting
Prior art date
Application number
DK16770031.9T
Other languages
English (en)
Inventor
Neil Patrick Grimster
Sameer Kawatkar
Jason Grant Kettle
Magnus K Nilsson
Linette Lys Ruston
Qibin Su
Melissa Marie Vasbinder
Jon James Winter-Holt
Dedong Wu
Wenzhan Yang
Tudor Grecu
James Mccabe
Richard Donald Woessner
Claudio Edmundo Chuaqui
Annika Birgitta Margareta ÿStrand
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3353168T3 publication Critical patent/DK3353168T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16770031.9T 2015-09-25 2016-09-22 Forbindelser og fremgangsmåder til at inhibere jak DK3353168T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562232629P 2015-09-25 2015-09-25
PCT/EP2016/072616 WO2017050938A1 (en) 2015-09-25 2016-09-22 Compounds and methods for inhibiting jak

Publications (1)

Publication Number Publication Date
DK3353168T3 true DK3353168T3 (da) 2023-10-02

Family

ID=56979589

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16770031.9T DK3353168T3 (da) 2015-09-25 2016-09-22 Forbindelser og fremgangsmåder til at inhibere jak

Country Status (17)

Country Link
US (5) US9714236B2 (da)
EP (2) EP4219482A1 (da)
JP (1) JP6767491B2 (da)
KR (2) KR20250035597A (da)
CN (4) CN108368091B (da)
AR (1) AR106138A1 (da)
AU (1) AU2016328764B2 (da)
BR (1) BR112018005833B1 (da)
CA (1) CA2995430C (da)
DK (1) DK3353168T3 (da)
ES (1) ES2956642T3 (da)
MX (1) MX375724B (da)
PT (1) PT3353168T (da)
RU (1) RU2760359C2 (da)
TW (1) TWI740843B (da)
WO (1) WO2017050938A1 (da)
ZA (1) ZA201800782B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714236B2 (en) * 2015-09-25 2017-07-25 Astrazeneca Ab Compounds and methods for inhibiting JAK
CA3023176A1 (en) 2016-05-26 2017-11-30 Zeno Royalties & Milestones, LLC Egfr inhibitor compounds
SG11201906222WA (en) 2017-01-17 2019-08-27 Astrazeneca Ab Jak1 selective inhibitors
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
AU2019304014B2 (en) * 2018-07-18 2022-08-18 Astrazeneca Ab A xinafoate salt of a jak inhibiting compound
CA3113732C (en) * 2018-09-21 2023-07-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US20220220096A1 (en) * 2019-04-19 2022-07-14 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Jak1 selective kinase inhibitor
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN111961037B (zh) * 2020-09-17 2021-09-21 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
JP7613778B2 (ja) * 2020-11-26 2025-01-15 科輝智薬(深▲セン▼)新薬研究中心有限公司 アミド化合物、医薬組成物およびその使用
WO2022189496A1 (en) * 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4937112B2 (ja) 2004-03-30 2012-05-23 バーテックス ファーマシューティカルズ インコーポレイテッド Jakおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
HRP20120824T1 (hr) 2005-10-28 2012-11-30 Astrazeneca Ab Derivati 4-(3-aminopirazol) pirimidina za uporabu kao inhibitori tirozin kinaze u lijeäśenju karcinoma
EA200870217A1 (ru) * 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
MX2009006081A (es) * 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
CN102458581B (zh) * 2009-05-22 2016-03-30 因塞特控股公司 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2012030910A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
AU2011328237A1 (en) * 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
SG190839A1 (en) * 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012116247A1 (en) * 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
PH12013502612A1 (en) * 2011-06-20 2014-04-28 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
KR102135601B1 (ko) 2012-03-29 2020-07-20 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법
US9714236B2 (en) * 2015-09-25 2017-07-25 Astrazeneca Ab Compounds and methods for inhibiting JAK

Also Published As

Publication number Publication date
PT3353168T (pt) 2023-09-20
TW201730186A (zh) 2017-09-01
KR20180058719A (ko) 2018-06-01
US11247983B2 (en) 2022-02-15
CN111848586A (zh) 2020-10-30
HK1259422A1 (zh) 2019-11-29
KR20250035597A (ko) 2025-03-12
US20170088543A1 (en) 2017-03-30
US20170320857A1 (en) 2017-11-09
JP2018529770A (ja) 2018-10-11
CN111646980B (zh) 2021-08-27
CN111606893A (zh) 2020-09-01
CN111646980A (zh) 2020-09-11
CN111848586B (zh) 2024-05-03
US9714236B2 (en) 2017-07-25
ES2956642T3 (es) 2023-12-26
BR112018005833B1 (pt) 2023-10-10
CA2995430C (en) 2023-07-11
EP4219482A1 (en) 2023-08-02
MX375724B (es) 2025-03-06
AU2016328764B2 (en) 2020-07-09
US20190092760A1 (en) 2019-03-28
EP3353168B1 (en) 2023-08-30
TWI740843B (zh) 2021-10-01
CN111606893B (zh) 2021-05-04
RU2018112993A (ru) 2019-10-28
EP3353168A1 (en) 2018-08-01
BR112018005833A2 (pt) 2018-10-16
JP6767491B2 (ja) 2020-10-14
US10654835B2 (en) 2020-05-19
CN108368091A (zh) 2018-08-03
US12319670B2 (en) 2025-06-03
CN108368091B (zh) 2020-08-11
CA2995430A1 (en) 2017-03-30
RU2018112993A3 (da) 2020-01-30
ZA201800782B (en) 2018-12-19
US20220119372A1 (en) 2022-04-21
KR102774784B1 (ko) 2025-02-27
RU2760359C2 (ru) 2021-11-24
US10167276B2 (en) 2019-01-01
AR106138A1 (es) 2017-12-13
AU2016328764A1 (en) 2018-02-22
MX2018003590A (es) 2018-11-29
WO2017050938A1 (en) 2017-03-30
US20210078981A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3353168T3 (da) Forbindelser og fremgangsmåder til at inhibere jak
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3227262T3 (da) Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3310371T3 (da) Glucagon og GLP-1-Co-agonistforbindelser
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3265947T3 (da) Fremgangsmåde og system til kryptering
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3108009T3 (da) Fremgangsmåder og sammensætninger til DNA-profilering
DK3112249T3 (da) System til behandling af boil-off-gas
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
HUE064003T2 (hu) JAK-gátló
DK3234160T3 (da) Sammensætninger og fremgangsmåder til hjælper-stamme-medieret svampegenommodifikation
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3125898T3 (da) Farmakofor til trail-induktion